Literature DB >> 24464352

Differential time preferences for money and quality of life.

M B Y Parouty1, H H Le, D Krooshof, M J Postma.   

Abstract

BACKGROUND: This study provides an empirical investigation into differential time preferences between money and quality of life. Thus far, time preference investigations in health have mostly involved life-years gained and lives saved. However, the quality-adjusted life-year, which is recommended by several bodies, is a multiplicative measure of life duration and quality of life. To our knowledge, our study is the first to follow this approach specifically for quality of life.
METHODS: A questionnaire was developed to elicit time preferences for quality of life and for money, and it was distributed to a representative sample of the Dutch population. We also investigated the impact of population characteristics, such as current health state, optimistic/pessimistic future views or gender, on time preferences.
RESULTS: We found that discount rates for both money and quality of life decrease with increasing time of delay, with rates of the former being consistently at least two times higher than those of the latter. Similar trends in time preferences were observed across the subgroups, with the exception of the relatively high education subgroup.
CONCLUSION: In agreement with the results of other studies, our empirically derived discount rates are higher than the rates featured in national guidelines for health care economic assessment. Our empirical study adds to the evidence for differential discounting, both with regards to money and health, as well as in time.

Mesh:

Year:  2014        PMID: 24464352     DOI: 10.1007/s40273-013-0124-8

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

1.  The estimation of marginal time preference in a UK-wide sample (TEMPUS) project.

Authors:  J A Cairns; M M van der Pol
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

2.  Time is on my side: optimism in intertemporal choice.

Authors:  M Berndsen; J van der Pligt
Journal:  Acta Psychol (Amst)       Date:  2001-09

3.  Private and social time preferences for health and money: an empirical estimation.

Authors:  A Lazaro; R Barberan; E Rubio
Journal:  Health Econ       Date:  2001-06       Impact factor: 3.046

4.  Saving lives in the present versus saving lives in the future--is there a framing effect?

Authors:  M Johannesson; P O Johansson
Journal:  J Risk Uncertain       Date:  1997-11

5.  Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.

Authors:  Karl Claxton; Mark Sculpher; Anthony Culyer; Chris McCabe; Andrew Briggs; Ron Akehurst; Martin Buxton; John Brazier
Journal:  Health Econ       Date:  2006-01       Impact factor: 3.046

6.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  Stuart Birks
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  WHO Guide for standardisation of economic evaluations of immunization programmes.

Authors:  Damian G Walker; Raymond Hutubessy; Philippe Beutels
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

8.  Towards a healthier discount procedure.

Authors:  Rogier M Klock; Werner Bf Brouwer; Lieven Jp Annemans; Jasper M Bos; Maarten J Postma
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2005-02       Impact factor: 2.217

Review 9.  Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination.

Authors:  Mark H Rozenbaum; Cornelis Boersma; Maarten J Postma; Eelko Hak
Journal:  Expert Rev Vaccines       Date:  2011-02       Impact factor: 5.217

10.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641

View more
  3 in total

Review 1.  Reducing the costs of chronic kidney disease while delivering quality health care: a call to action.

Authors:  Raymond Vanholder; Lieven Annemans; Edwina Brown; Ron Gansevoort; Judith J Gout-Zwart; Norbert Lameire; Rachael L Morton; Rainer Oberbauer; Maarten J Postma; Marcello Tonelli; Wim Van Biesen; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2017-05-30       Impact factor: 28.314

2.  Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Authors:  Bernhard Ultsch; Oliver Damm; Philippe Beutels; Joke Bilcke; Bernd Brüggenjürgen; Andreas Gerber-Grote; Wolfgang Greiner; Germaine Hanquet; Raymond Hutubessy; Mark Jit; Mirjam Knol; Rüdiger von Kries; Alexander Kuhlmann; Daniel Levy-Bruhl; Matthias Perleth; Maarten Postma; Heini Salo; Uwe Siebert; Jürgen Wasem; Ole Wichmann
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

3.  Economic evaluation of meningococcal vaccines: considerations for the future.

Authors:  Hannah Christensen; Hareth Al-Janabi; Pierre Levy; Maarten J Postma; David E Bloom; Paolo Landa; Oliver Damm; David M Salisbury; Javier Diez-Domingo; Adrian K Towse; Paula K Lorgelly; Koonal K Shah; Karla Hernandez-Villafuerte; Vinny Smith; Linda Glennie; Claire Wright; Laura York; Raymond Farkouh
Journal:  Eur J Health Econ       Date:  2019-11-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.